Archive

Filter

Although September is historically the worst month of the year for the stock market, the second half of this month could be much better than the historical average. Read More

While Organon’s management team has worked diligently to build its biosimilars business, Wall Street has bided its time waiting to see proof that it could successfully navigate that transition. Read More